carvedilol has been researched along with Malignant Melanoma in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent studies suggest that the β-blocker drug carvedilol prevents skin carcinogenesis but the mechanism is unknown." | 3.88 | Phosphoproteome profiling provides insight into the mechanism of action for carvedilol-mediated cancer prevention. ( Andresen, BT; Cleveland, KH; Huang, KM; Huang, Y; Liang, S; Yeung, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Q | 1 |
| Long, J | 1 |
| Hu, L | 1 |
| Chen, Z | 1 |
| Li, Q | 1 |
| Hu, G | 1 |
| Muhailan, M | 1 |
| Al-Shbool, G | 1 |
| Cleveland, KH | 1 |
| Yeung, S | 1 |
| Huang, KM | 1 |
| Liang, S | 1 |
| Andresen, BT | 1 |
| Huang, Y | 1 |
3 other studies available for carvedilol and Malignant Melanoma
| Article | Year |
|---|---|
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Dru | 2020 |
Pseudo-Wellens' Syndrome Temporally Associated With Immune Check Point Inhibitors Use.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antineoplast | 2020 |
Phosphoproteome profiling provides insight into the mechanism of action for carvedilol-mediated cancer prevention.
Topics: Adrenergic beta-Antagonists; Animals; Anticarcinogenic Agents; Carcinogenesis; Carvedilol; Epidermal | 2018 |